Efficacy of erlotinib in patients with advanced Non-small-cell Lung Cancer (NSCLC): Analysis of the Australian subpopulation of the TRUST study
Michael Boyer, Keith Horwood, Nick Pavlakis, Paul De Souza, Michael Millward, Brian Stein, Michael Johnston, Fiona Abell, Danny Rischin
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY | WILEY-BLACKWELL | Published : 2012
AIMS: The efficacy of erlotinib (Tarceva, Roche Products, Dee Why, Australia) has been demonstrated in patients with advanced non-small-cell lung cancer (NSCLC). Tarceva lung cancer survival treatment (TRUST) is an open-label, single-arm, phase IV global trial which investigated erlotinib in advanced NSCLC patients who had failed prior therapy or were unsuitable for chemo/radiotherapy. The aim of this analysis was to report the safety and efficacy of erlotinib in the Australian patient subpopulation. METHODS: Patients with stage IIIB/IV NSCLC progressing after standard systemic chemotherapy or unsuitable to receive chemo/radiotherapy were eligible for the study. The patients were treated wit..View full abstract
The authors would like to thank all study investigators, coordinators and patients who participated in the study. We would also like to thank Daniel Gregory and the Roche study team. Medical writing assistance was provided by Dr Joseline Ojaimi from Roche Products, Australia. The TRUST study was sponsored by F. Hoffmann-La Roche.